Loading resource…

University Medical Center Groningen, University of Groningen
The clinical benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD) have been well established through major clinical outcome trials. Secondary analyses from these trials suggest consistent benefits across various subgroups, including those with severe CKD and kidney transplant recipients. However, the document emphasizes the necessity for more research to ascertain the safety and efficacy of SGLT2 inhibitors in these specific populations, particularly concerning the risk of urinary tract infections and other side effects.
Sign in to open
Answers use this document only.
Your first question is free.
Resources from the same specialty and type. Curated links will replace these when added.
Documents that extend or complement this resource.

CARDIOVASCULAR COMPLICATIONS IN CHRONIC KIDNEY DISEASE: A REVIEW FROM THE EUROPEAN RENAL AND CARDIOVASCULAR MEDICINE WORKING GROUP OF THE EUROPEAN RENAL ASSOCIATION
Same clinical topic · Nephrology

THE ASSOCIATION BETWEEN DUAL RAAS INHIBITION AND RISK OF ACUTE KIDNEY INJURY AND HYPERKALEMIA IN PATIENTS WITH DIABETIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Same clinical topic · Nephrology

OBESITY IN CKD: CORE CURRICULUM 2026
Same clinical topic · Nephrology

OBESITY IN CKD: CORE CURRICULUM 2026
Same clinical topic · Nephrology

ACUTE GLOMERULONEPHRITIS
Same clinical topic · Nephrology

DISEASE MODIFICATION IN LUPUS NEPHRITIS: TOWARDS A PATHOPHYSIOLOGY-BASED TREATMENT PARADIGM
Same clinical topic · Nephrology

Effects of correction rate for severe hyponatremia in the intensive care unit on patient outcomes
Same clinical topic · Nephrology

CURRENT UNDERSTANDING OF SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS IN CARDIOVASCULAR-KIDNEY-METABOLIC SYNDROME
Same clinical topic · Nephrology

A COMPREHENSIVE REVIEW OF ACUTE CARDIO-RENAL SYNDROME: NEED FOR NOVEL BIOMARKERS
Same clinical topic · Nephrology